Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel(NSCLC) | completed | Phase 1 / Phase 2 | 116 | Ionis Pharmaceuticals, Inc.INDUSTRY | 4 | Jun 27, 2018 | clinicaltrials |
| NCT00445198 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | completed | Phase 1 / Phase 2 | 86 | AbbVie (prior sponsor, Abbott)INDUSTRY | 3 | Jun 6, 2018 |
| clinicaltrials |
| NCT01139775 | A Study in Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 76 | Eli Lilly and CompanyINDUSTRY | 2 | May 18, 2018 | clinicaltrials |
| NCT01204099 | Study of PX-866 and Docetaxel in Solid Tumors | completed | Phase 1 / Phase 2 | 223 | Cascadian Therapeutics Inc.INDUSTRY | 2 | May 16, 2018 | clinicaltrials |
| NCT03515252 | Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer | completed | Phase 1 | 20 | Ivy Life Sciences, Co., LtdINDUSTRY | 0 | May 9, 2018 | clinicaltrials |
| NCT00078390 | Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | ShionogiINDUSTRY | 1 | May 2, 2018 | clinicaltrials |
| NCT01588145 | Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients | completed | Phase 1 / Phase 2 | 273 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT01998126 | Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | completed | Phase 1 | 14 | University of UtahOTHER | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | completed | Phase 1 | 112 | Merrimack PharmaceuticalsINDUSTRY | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00923312 | Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 46 | CureVacINDUSTRY | 2 | Mar 20, 2018 | clinicaltrials |
| NCT01809210 | Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer(SELECT-3) | completed | Phase 1 | 55 | AstraZenecaINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00399789 | A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | AEterna ZentarisINDUSTRY | 1 | Feb 22, 2018 | clinicaltrials |
| NCT00372515 | High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations | completed | Phase 1 | 7 | David M. Jackman, MDOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT00455052 | A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Mersana TherapeuticsINDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02014337 | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | completed | Phase 1 | 37 | Corcept TherapeuticsINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00599755 | Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3) | completed | Phase 1 | 68 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 16, 2018 | clinicaltrials |
| NCT01336842 | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | completed | Phase 1 | 23 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT02194049 | Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer | completed | Phase 1 | 3 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT02172846 | Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer | completed | Phase 1 | 23 | Washington University School of MedicineOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00093756 | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00654758 | A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 33 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01225302 | A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 12 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00528281 | A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 4 | Nov 17, 2017 | clinicaltrials |
| NCT00619424 | A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT00259935 | A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 2 | Nov 14, 2017 | clinicaltrials |
| NCT00678977 | A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors | completed | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 2 | Nov 14, 2017 | clinicaltrials |
| NCT00866528 | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT00946673 | Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer | completed | Phase 1 | 17 | Stanford UniversityOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT01995188 | A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT03001609 | Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC | completed | Phase 1 | 7 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01987232 | Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | AmgenINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00856830 | Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT01733589 | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC | completed | Phase 1 / Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT01051934 | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | completed | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01233687 | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 49 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT01363947 | Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer | completed | Phase 1 | 87 | Genentech, Inc.INDUSTRY | 2 | Jun 7, 2017 | clinicaltrials |
| NCT00046111 | A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors | completed | Phase 1 | 1 | GlaxoSmithKlineINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT00731952 | Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer | completed | Phase 1 | 21 | University of VirginiaOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT02369198 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | completed | Phase 1 | 27 | Asbestos Diseases Research FoundationOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | completed | Phase 1 / Phase 2 | 88 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT01069757 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 16 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01251796 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 9 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT01005797 | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | completed | Phase 1 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00444015 | Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01647711 | A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations | completed | Phase 1 | 35 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jun 27, 2018source: clinicaltrials